Septerna (SEPN) stock

Oral small molecule drugs , market cap $2.2B

Oral small molecule drugs for GPCR

Worth $2.2B

$52.34

+3.15%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Excellent

In its industry

#21of 281

Biotech

Checks firing

7of 14

Trending up

From 52-week high

-0.4%

under its best in a year

SEPN's Quality Score fell 2 points on Tue, Nov 10, to 15. Its daily price swings got bigger (2 chart checks stopped).

Follow SEPN's trial news. Pro members can get an alert when Septerna files news, and see its trials, share raises, and its CEO's filings.

Get an alert when SEPN files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ1 2027“…for hypoparathyroidism, is ongoing in healthy volunteers, with data expected in the first quarter of 2027…”Trial data · SEC filing · Nov 9

Why is SEPN up?

Up 21% from Nov 2 to Nov 10.

Its Nov 9 results release reported quarterly revenue of $18.9M, and its close that day was its highest in more than 2 years of closes.

Sources: Price history, Nov 10, 2026; SEC filing, Nov 9, 2026; Company release (8-K), Nov 9, 2026

1 more reason, free with an account →1 more reason why SEPN rose 21% since Nov 2, from its filings, with the company's words, the timeline, and its peers, for Pro members.

Key facts on SEPN

Key facts on SEPN
The chart	Stronger than 98% of stocks over the last 3 months
Latest filing	8-K, Nov 9 Reported its quarterly results

1 more reason behind SEPN's 15, free with an account →5 more reasons behind SEPN's 15, for Pro members.

SEPN in the news

ReportLast night: sales of $18.9M; a loss of $0.57 a share. Past reports ›

Wed Nov 4Form 8K Septerna Inc For: 4 November By Investing.com investing.com canada and 1 more SEPN closed +9.6% that day.

What's next

Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.

3 more dates ahead: conferences, for Pro members.

SEPN catalysts

Coming up

After its last 4 reports it closed +7.0% on average, higher 3 of 4 times.

3 past catalysts since 2025, with sizes and sources, for Pro members.

What's next for SEPN, and how long its cash lasts

Next step the company has named

Q1 2027“…clinical trial of SEP-479, an oral small molecule PTH1R agonist in development for hypoparathyroidism, is ongoing in healthy volunteers, with data expected in the first quarter of 2027.”Trial data · SEC filing · Nov 9

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: SEP-479 · Healthy Volunteers · Phase 1
Its trial: Single and Multiple Doses of SEP-479 in Healthy Adult ParticipantsPhase 1 · Recruiting · 150 people · main data estimated Feb 2027 · NCT07433179

For Pro members: 1 more milestone and 28 filings.

Cash runway

The company says its cash lasts into mid-2029 (8-K, Nov 9).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Mar 10, 2026)
At-the-market share sales program (S-3ASR, filed Mar 10, 2026)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

President and COO Elizabeth Bhatt sold 4,000 shares on Oct 15, under a planned sale. 14 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Jeffrey Finer buys or sells

For Pro members: every trade, and Jeffrey Finer’s 13 filings and quotes.

Get an alert when SEPN files news on its trialA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why SEPN scores 15

Excellentfor quality, not price, 7 of 14 chart checks firingWhat the Quality Score means

+7Chart checks 7 of 14 firing right now, one point each
+4Long-term trend above a rising 200-⁠day average, near its 52-⁠week high, at a multi-⁠year high

Run-up adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
Persistence adds

No effect today: Size, Dilution, and News.

What every line is worth, and the reason behind it, on SEPN and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when SEPN's Quality Score turns up

A free account. No card.

How SEPN ranks in Biotech

SEPN is #21 of 281 by Quality Score.

How SEPN ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	RYTMRhythm Pharmaceuticals		Open for its score
	SCTXScribe Therapeutics		Open for its score
	SGMTSagimet Biosciences		Open for its score
	SIONSionna Therapeutics		Open for its score
21	SEPNSepterna	7/14	15

Share count against a year before: SEPN +5.8%, BHVN +43%, MBX +42%, ELVN +26%.

When does SEPN report earnings, and what happens after?

Expected to report Mon Mar 8, after the close (in 118 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What SEPN reported on Nov 9, 2026

The quarter

Sales of $18.9M, 12% less than a year ago; a loss of $0.57 a share, from a profit of $0.18.

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

SEPN's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“Septerna expects its existing cash runway to fund operations at least into mid-2029.”

From its results filing (SEC filing · Nov 9)

The numbers

Market value: $2.2B; today
Sales: $96.3M; up 337% on the year
Free cash flow: -$77.6M; last 12 months

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on SEPN: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+5.4%+22.9%+3.1%

May 11Aug 10Nov 9

Reported	When	Gap	Reaction	5 days
Nov 9, 2026After close	After close	-2.7%	+3.1%	not yet
Aug 10, 2026After close	After close	+1.9%	+22.9%	+13.8%
May 11, 2026After close	After close	+3.8%	+5.4%	+11.6%

SEPN closed higher after 3 of its last 4 reports.

All 4 reports, and SEPN's Quality Score going into each

SEPN sales and profit by year

Sales and profit by year

Sales grew every year from 2023 to 2025, to $46M. It made a profit in one of the three years.

SEPN has 7 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on SEPN, and all 14 on every stock.Get in free →

SEPN RSI today: 77.9, above its 50-day and 200-day averages

Not scored

RSI 77.9, MACD above signal, above both averages. Not scored.13 readings

The deep dive on SEPN

What it does and how it makes money2 findingsAn operating loss of $68.3M in fiscal 2025, on $46.0M of sales.Annual report, filed Mar 9, 2026
Where it stands2 findingsFor Pro members2 findings on where SEPN stands: its cash, debt, and share count, for Pro members
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades SEPN, for Pro members
Against its closest peers4 peersShare count against a year before: SEPN +5.8%, BHVN +43%, MBX +42%, ELVN +26%.

6 more findings on SEPN, each with its source, for Pro members.

SEPN share count over time

Shares: 5.8% more than a year ago (to Sep 30).

Shares of SEPN outstanding, as filed
Shares outstanding	As of
47.5M	Nov 4, 2026
46.7M	Aug 5, 2026
45.1M	May 7, 2026
44.9M	Mar 2, 2026

Offerings, shelves, and splits of SEPN, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Mar 10, 2026
Raised $288M in a sale of shares, about 13% of its market value	Oct 25, 2024
Registered shares for sale (S-1)	Oct 2, 2024

SEPN insider trades

One insider sold $31.7M across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellRa Capital Management, L.P.$31.7M10% ownerat $42.50 on Aug 12, filed Aug 14

SellRa Capital Management, L.P.10% owner$31.7Mat $42.50 on Aug 12, filed Aug 14

SEPN's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Elizabeth BhattPresident and COO · 5 trades
Samira ShaikhlyChief People Officer · 5 trades
Daniel D. LongSVP, Drug Discovery · 5 trades

See insider trades by person

Which ETFs hold SEPN?

In ETFs: SEPN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Septerna

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

130 employeesSouth San Francisco, CAsepterna.com

What Septerna says it competes with

“We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us.”

From its annual report, SEC filing · Mar 9, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on SEPN and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move SEPN's score: 4 things
6 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayAug 14Ra Capital Management, L.P. sold SEPN$31.7M at $42.50, filed Aug 14

Alerts are optional.

See SEPN's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: SEPN's Quality Score is 15 (Excellent), #21 of 281 in Biotech. Insiders sold $31.7M in the last 6 months (Form 4).

What does SEPN's Quality Score say?

SEPN scores 15 today, which Breakaway calls Excellent. It is #21 of 281 in Biotech by Quality Score, with 7 of 14 chart checks firing. Up 21% from Nov 2 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is SEPN's Quality Score?

SEPN scores 15 today, which Breakaway calls Excellent (15 to 19). That is #21 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SEPN's 15.

Are insiders buying SEPN?

One insider sold $31.7M across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is Ra Capital Management, L.P., 10% owner, who sold $31.7M on Aug 12.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.